Lobe Sciences Announces Validation of European Unitary Patent for DHA-Based Composition for Sickle Cell Disease
Lobe Sciences (OTCQB:LOBEF) has announced the validation of its European Unitary Patent EP4117446 across 17 EU member states for its DHA-based composition targeting Sickle Cell Disease (SCD).
The patent specifically covers 础濒迟别尘颈补庐, a physician-supervised medical food formula designed to address long-chain fatty acid deficiencies in SCD patients. The formulation combines DHA and natural emulsifiers to improve bioavailability and restore red blood cell membrane integrity.
This validation represents a significant expansion of Lobe's intellectual property protection in key European markets, strengthening the company's position for broader commercialization of 础濒迟别尘颈补庐.
Lobe Sciences (OTCQB:LOBEF) ha annunciato la convalida del suo Brevetto Unitario Europeo EP4117446 in 17 stati membri dell'UE per la sua composizione a base di DHA destinata alla cura della Sickle Cell Disease (SCD).
Il brevetto riguarda specificamente 础濒迟别尘颈补庐, una formula alimentare medica supervisionata da medici, progettata per correggere le carenze di acidi grassi a catena lunga nei pazienti con SCD. La formulazione combina DHA ed emulsionanti naturali per migliorare la biodisponibilit脿 e ripristinare l'integrit脿 della membrana dei globuli rossi.
Questa convalida rappresenta un'importante espansione della protezione della propriet脿 intellettuale di Lobe nei principali mercati europei, rafforzando la posizione dell'azienda per una commercializzazione pi霉 ampia di 础濒迟别尘颈补庐.
Lobe Sciences (OTCQB:LOBEF) ha anunciado la validaci贸n de su Patente Unitaria Europea EP4117446 en 17 estados miembros de la UE para su composici贸n basada en DHA dirigida a la enfermedad de c茅lulas falciformes (SCD).
La patente cubre espec铆ficamente 础濒迟别尘颈补庐, una f贸rmula alimentaria m茅dica supervisada por m茅dicos, dise帽ada para corregir deficiencias de 谩cidos grasos de cadena larga en pacientes con SCD. La formulaci贸n combina DHA y emulsionantes naturales para mejorar la biodisponibilidad y restaurar la integridad de la membrana de los gl贸bulos rojos.
Esta validaci贸n representa una expansi贸n significativa de la protecci贸n de la propiedad intelectual de Lobe en mercados clave europeos, fortaleciendo la posici贸n de la compa帽铆a para una comercializaci贸n m谩s amplia de 础濒迟别尘颈补庐.
Lobe Sciences (OTCQB:LOBEF)電� 雮爜順堦惮氤�(SCD)鞚� 瓴儱頃� DHA 旮半皹 臁办劚氍检棎 雽�頃� 鞙犽熃 雼澕 韸鬼棃 EP4117446鞚� 17臧� EU 須岇洂甑�鞐愳劀 鞙犿毃頃潉 氚滍憸頄堨姷雼堧嫟.
鞚� 韸鬼棃電� 韸鬼瀳 鞚橃偓臧� 臧愲弲頃橂姅 鞚橂鞖� 鞁濏拡 鞝滍槙鞚� 础濒迟别尘颈补庐毳� 韽暔頃橂┌, SCD 頇橃瀽鞚� 鞛レ噭 歆�氚╈偘 瓴绊晬鞚� 頃搓舶頃橁赴 鞙勴暣 靹り硠霅橃棃鞀惦媹雼�. 鞚� 鞝滍槙鞚� DHA鞕� 觳滌棸 鞙犿檾鞝滊ゼ 瓴绊暕頃橃棳 靸濎泊鞚挫毄毳犾潉 雴掛澊瓿� 鞝來槇甑� 毵夓潣 鞕勳爠靹膘潉 須岆车頃╇媹雼�.
鞚措矆 鞙犿毃靹� 頇曥澑鞚� 欤检殧 鞙犽熃 鞁滌灔鞐愳劀 Lobe鞚� 歆�鞝� 鞛偘甓� 氤错樃毳� 韥矊 頇曥灔頃橂姅 瓴冹溂搿�, 础濒迟别尘颈补庐鞚� 氤措嫟 甏戨矓鞙勴暅 靸侅毄頇旊ゼ 鞙勴暅 須岇偓鞚� 鞛呾毳� 臧曧檾頃╇媹雼�.
Lobe Sciences (OTCQB:LOBEF) a annonc茅 la validation de son Brevet Unitaire Europ茅en EP4117446 dans 17 脡tats membres de l'UE pour sa composition 脿 base de DHA ciblant la dr茅panocytose (SCD).
Le brevet couvre sp茅cifiquement 础濒迟别尘颈补庐, une formule alimentaire m茅dicale supervis茅e par des m茅decins, con莽ue pour corriger les carences en acides gras 脿 cha卯ne longue chez les patients atteints de SCD. La formulation combine DHA et 茅mulsifiants naturels pour am茅liorer la biodisponibilit茅 et restaurer l'int茅grit茅 de la membrane des globules rouges.
Cette validation repr茅sente une expansion significative de la protection de la propri茅t茅 intellectuelle de Lobe sur les march茅s europ茅ens cl茅s, renfor莽ant la position de la soci茅t茅 pour une commercialisation plus large d'础濒迟别尘颈补庐.
Lobe Sciences (OTCQB:LOBEF) hat die Validierung seines europ盲ischen Einheitspatents EP4117446 in 17 EU-Mitgliedstaaten f眉r seine DHA-basierte Zusammensetzung zur Behandlung der Sichelzellenkrankheit (SCD) bekannt gegeben.
Das Patent deckt speziell 础濒迟别尘颈补庐 ab, eine 盲rztlich 眉berwachte medizinische Nahrungserg盲nzung, die entwickelt wurde, um Langkettige Fetts盲uredefizite bei SCD-Patienten auszugleichen. Die Formulierung kombiniert DHA und nat眉rliche Emulgatoren, um die Bioverf眉gbarkeit zu verbessern und die Integrit盲t der roten Blutk枚rperchenmembran wiederherzustellen.
Diese Validierung stellt eine bedeutende Erweiterung des geistigen Eigentumsschutzes von Lobe in wichtigen europ盲ischen M盲rkten dar und st盲rkt die Position des Unternehmens f眉r eine breitere Kommerzialisierung von 础濒迟别尘颈补庐.
- Patent protection secured in 17 European Union member states
- First-in-class emulsified oral formulation for SCD treatment
- Strengthened intellectual property portfolio for European market expansion
- Romania's patent protection delayed until September 1, 2024
European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease.
Covers Altemia(R) Medical Food Formula - The patented composition underpins Altemia(R), a physician-supervised medical food formulated to address long-chain fatty acid deficiencies common in SCD patients.
Supports Global Expansion Strategy - Validation strengthens Lobe's IP portfolio and enables broader commercialization of Altemia(R) across key European markets.
VANCOUVER, BC / / July 8, 2025 / Lobe Sciences Ltd. (CSE:LOBE), (OTCQB:LOBEF), (FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that the European Patent Office has officially validated the company's European Patent EP4117446 as a Unitary Patent.
Titled "A Composition Comprising Docosahexaenoic Acid鈥� for Sickle Cell Disease Treatment," the patent covers novel formulations combining DHA and ingredients specifically designed to address fatty acid deficiencies and related complications in Sickle Cell Disease (SCD).
This Unitary Patent provides Lobe Sciences with intellectual property protection across 17 European Union member states, including Austria, Belgium, Bulgaria, Germany, Denmark, Estonia, Finland, France, Italy, Lithuania, Luxembourg, Latvia, Malta, Netherlands, Portugal, Romania (from September 1, 2024), Sweden, and Slovenia.
The validation marks a significant milestone in Lobe's efforts to broaden the global footprint of 础濒迟别尘颈补庐 Medical Food, which is based on this composition. Altemia is a first-in-class emulsified oral formulation developed to restore red blood cell membrane integrity in patients with SCD. The formula leverages DHA and natural emulsifiers to improve bioavailability and effectiveness in managing long-chain fatty acid deficiencies-a hallmark of SCD pathology.
"With this Unitary Patent in place, we are better positioned to protect and expand the reach of our proprietary SCD treatment technology throughout Europe," said Dr. Fred D. Sancilio, CEO of Lobe Sciences. "This is an important step as we continue our mission to deliver nutritional and therapeutic innovations for patients with rare and neglected diseases."
About Lobe Sciences - Lobe Sciences Ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) is a biopharmaceutical company focused on developing innovative therapies for rare and underserved conditions. Through its wholly owned subsidiary, Altemia, Inc., and its majority-owned subsidiary, Cynaptec Pharmaceuticals, Inc., Lobe is advancing a patented lipid-based platform for treating Sickle Cell Disease and a novel oral analog of psilocin-Conjugated Psilocin鈩�-targeted at Chronic Cluster Headache and other neurological disorders. These programs address significant unmet medical needs with the potential to improve outcomes in both hematologic and neuropsychiatric patient populations.
For further information:
Dr. Fred D. Sancilio, CEO
Lobe Sciences Ltd.
Investor and Media
[email protected]
Phone: +1 (949) 505-5623
Cautionary Statement Regarding "Forward-Looking" Information
This news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including, without limitation: the Company's intention to raise funds for clinical trials, the innovativeness of Conjugated PsilocinTM. the anticipated focus and timing or efficiency of the Company's research and development activities; the potential for the Company's products to meet unmet medical needs, the anticipated use of proceeds from the offering, the intended development plans for Cynaptec, the intention of Lobe Sciences to provide certain services to Cynaptec, the potential exercise of the option and intended use of proceeds therefrom and the potential ability to raise funds for clinical development are forward-looking statements and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should" or "would" or occur.
Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including, among other things, that: the Company's planned activities will be able to create shareholder value and address serious unmet medical needs; the Company will continue to pursue its planned research and development activities, and that the Company will be able to raise funds among others. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important risks that may cause actual results to vary, include, without limitation, the risk that: the Company's planned activities will be unable to create shareholder value or address the targeted unmet medical needs; the Company is unable to obtain the desired results from its current research and development activities; and the Company is unable to raise funds or to do so on the timelines anticipated.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ACCURACY OR ADEQUACY OF THIS NEWS RELEASE.
SOURCE: Lobe Sciences Ltd.
View the original on ACCESS Newswire
FAQ
What is the significance of Lobe Sciences' (LOBEF) European Unitary Patent validation?
What is 础濒迟别尘颈补庐 and how does it treat Sickle Cell Disease?
Which European countries are covered by Lobe Sciences' new patent?
How does this patent validation affect Lobe Sciences' business strategy?
